© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
August 30, 2022
Dr. Marc Matrana closes the discussion with considerations for clinicians on treating patients with prostate cancer.
Insight on recent developments and emerging options in the mCSPC treatment landscape.
An experienced clinician expands on effective strategies for monitoring patients with mCSPC during and after treatment and reviews patient expectations following disease progression.
Discussion centered around androgen receptor inhibition/androgen synthesis inhibition and comparison of available, approved options for each.
Clinical insights concerning the selection of effective treatment approaches for patients with mCSPC with comments on the study design and results of the TITAN study.
A prostate cancer expert shares a brief overview of available first-line therapy options for patients with mCSPC.